Table 3 (Abstract P26). Characteristics and responses of treated patients
Age/Gender | Prior Treatments | M Classification and Metastatic Sites | Response | Response Duration (months) | |
|---|---|---|---|---|---|
1 | 54 F | Anti-CLA-4, interferon (IFN) | M1c: Mesentery, small bowel, lymph nodes (LN) | PR | 8 |
2 | 34 F | Anti-PD1, anti-CLA-4, IFN, IL-2 + radiation (XRT), temozolomide | M1c: Brain, kidneys, adrenals, bone, liver, LN, subcutaneous (SC) | SD | 3 |
3 | 61 M | IL-2, BRAF inhibitor | M1c: Brain, liver, lungs, SC, mesentery, chest wall | PD (Progression in brain, but PR in extracranial sites) | 8, for extracranial response |
4 | 27 F | IL-2, anti-CTLA-4+IL-21, anti-CTLA-4 + XRT, recombinant IL-15 | M1c: Brain, SC, LN, pleura, kidneys, peritoneum | SD | 3 |
5 | 63 M | Anti-CTLA-4 | M1a: Intramuscular, LN | CR | 17, ongoing |
6 | 52 M | Anti-CTLA-4 | M1a: SC, LN | CR | 20, ongoing |
7 | 31 F | Anti-PD1, anti-CTLA-4, decarbazine, BRAF/MEK inhibitor | M1c: Brain, lungs, liver, SC | SD | 5 |